Effectiveness of Rifabutin for Treatment of Helicobacter Pylori

• Status: Not yet recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine the effectiveness of rifabutin triple therapy for the treatment of H. pylori infection in the Israeli population. Patients with or without a prior history of H. pylori eradication failure will be randomized to receive one of three possible treatments:

Group 1-amoxicillin 1000mg bd and rifabutin 150 mg bd and esomeprazole 40 mg bd Group 2- amoxicillin 1000mg bd and rifabutin 150 mg d and esomeprazole 40 mg bd Group 3- standard of care

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rabin Medical Center
• Treatments: Amoxicillin; Clarithromycin; Esomeprazole; Rifabutin; Tinidazole

Criteria

Inclusion Criteria:

• Patients presenting to outpatient clinic with evidence of H. pylori infection

Exclusion Criteria:

• allergy to any of the study drugs

• prior exposure to rifamycin drugs

• inability to provide informed consent

• pregnancy or lactation

• liver disease

• haematological disease

• renal failure

• active malignancy

• immune suppression

• patients not expected to benefit from Helicobacter pylori eradication